SRRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sierra Oncology's enterprise value is $1,074.42 Mil. Sierra Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $-102.30 Mil. Therefore, Sierra Oncology's EV-to-EBITDA for today is -10.50.
The historical rank and industry rank for Sierra Oncology's EV-to-EBITDA or its related term are showing as below:
During the past 9 years, the highest EV-to-EBITDA of Sierra Oncology was -0.03. The lowest was -10.50. And the median was -2.06.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-16), Sierra Oncology's stock price is $54.99. Sierra Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-6.770. Therefore, Sierra Oncology's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Sierra Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sierra Oncology Annual Data | |||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | ||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -2.24 | 0.05 | 1.81 | -1.15 | -2.49 |
Sierra Oncology Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -1.54 | -2.08 | -2.56 | -2.49 | -4.83 |
For the Biotechnology subindustry, Sierra Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sierra Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sierra Oncology's EV-to-EBITDA falls into.
Sierra Oncology's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 1074.421 | / | -102.3 | |
= | -10.50 |
Sierra Oncology's current Enterprise Value is $1,074.42 Mil.
Sierra Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-102.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sierra Oncology (NAS:SRRA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sierra Oncology's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 54.99 | / | -6.770 | |
= | At Loss |
Sierra Oncology's share price for today is $54.99.
Sierra Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Sierra Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivo Opportunity Fund Holdings, L.p. | director, 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
William D. Turner | officer: Chief Reg & Tech Ops Officer | C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404 |
Mary Christina Thomson | officer: General Counsel | C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404 |
Joshua Richardson | director, 10 percent owner | C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
Longitude Prime Fund, L.p. | 10 percent owner | 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
Longitude Prime Partners, Llc | 10 percent owner | 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
Gaurav Aggarwal | director, 10 percent owner | C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025 |
Llp Abingworth | 10 percent owner | 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Vivo Opportunity Fund, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Andrew Sinclair | director | C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Craig A Collard | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Georgia Erbez | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Christy J. Oliger | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
From GuruFocus
By Business Wire Business Wire • 01-27-2022
By GuruFocus Research GuruFocus Editor • 10-13-2022
By Business Wire Business Wire • 04-06-2022
By Business Wire Business Wire • 05-12-2022
By Business Wire Business Wire • 02-18-2022
By GuruFocus Research GuruFocus Editor • 05-18-2022
By Business Wire Business Wire • 05-05-2022
By Business Wire Business Wire • 01-31-2022
By Business Wire Business Wire • 01-19-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.